Treatment of Adult ADHD With Atomoxetine or Atomoxetine and Buspar

Pfizer241 enrolled

Overview

Determine if there is a difference in treatment response for adults with ADHD who are treated with Strattera versus those treated with a combination of Strattera and buspirone

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

241

Conditions

Attention Deficit Disorder With Hyperactivity

Interventions

AtomoxetineDRUG

BuspironeDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 55 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adults with ADHD Exclusion Criteria: * Other Axis I Psychiatric Disorders

Locations (11)

Pfizer Investigational Site

Los Angeles, California, United States

Pfizer Investigational Site

San Diego, California, United States

Pfizer Investigational Site

San Diego, California, United States

Outcomes

Primary Outcomes

To assess the efficacy of Atomoxetine-Buspirone (ATX-BSP) vs placebo (PBO) and atomoxetine (ATX) monotherapy in adult patients with ADHD as measured by the mean change across 7 weeks in the Adult ADHD Investigator Symptom Rating Scale (AISRS) total score

Secondary Outcomes

To characterize the safety over 8 weeks of ATX-BSP as compared to PBO and ATX monotherapy. To assess the response rate for the 3 treatment groups based on AISRS and CGI scores.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.